Fri.May 24, 2024

article thumbnail

Study Reveals Robust Benefits of Semaglutide in Protecting Against Kidney, CV Events in Patients With T2D

Drug Topics

Semaglutide reduced the risk of major kidney disease and cardiovascular (CV) events, and death from any cause, while simultaneously decelerating the loss of kidney function, among patients with type 2 diabetes (T2D) and CKD compared to placebo.

211
211
article thumbnail

New evidence supports fear that drinking raw milk containing bird flu viruses may be dangerous

STAT

A new study published Friday provides more evidence of the potential danger of drinking unpasteurized, or raw, milk containing H5N1 avian flu viruses. The work , published in the New England Journal of Medicine, showed that mice that were fed milk from H5N1-infected cows became very ill.

144
144
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Diagnostic Accuracy, Antibiotic Use Must Be Improved in C. Diff Infections

Drug Topics

In an abstract presented at Digestive Disease Week 2024, researchers analyzed Clostridioides difficile episodes and identified the risk factors and potential medications that caused them.

123
123
article thumbnail

Study Finds Semaglutide Improves Chronic Kidney Disease in Patients With Type 2 Diabetes

Pharmacy Times

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.

144
144
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Latest Ozempic results 'move the needle' for treating patients with diabetes, chronic kidney disease: Novo exec

Fierce Pharma

While it’s hard to overstate the success Novo Nordisk’s GLP-1 franchise has already achieved, the company’s latest deep dive into semaglutide data in chronic kidney disease (CKD) could help set a n | Early Friday, Novo shared full, positive results from the FLOW trial assessing the ability of once-weekly semaglutide 1.0 mg to help combat major kidney outcomes such as kidney failure, loss of kidney function and death from kidney or cardiovascular causes in people with Type 2 diabetes and chronic

128
128
article thumbnail

STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease

STAT

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population. Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new re

127
127

More Trending

article thumbnail

This week in clinical trials: 20th to 24th May

pharmaphorum

Exciting advancements in the world of clinical trials - Arecor Therapeutics, Faron, AstraZeneca, Volta Medical, J&J, Pneumagen, and Nimbus Therapeutics make headlines. Dive into this week's top stories impacting the future of medicine.

119
119
article thumbnail

Podcast: Litigation Lawyer on PBMs and Defending Independent Pharmacies

Drug Topics

Experienced litigation lawyer Mark Cuker sat down with Drug Topics to discuss pharmacy benefit managers and their often corrupt practices.

article thumbnail

ASCO: AffyImmune claims a first with CAR-T for solid tumours

pharmaphorum

AffyImmune Therapeutics has recorded what it says is the first documented complete response in a patient with a solid tumour treated with CAR-T therapy. The case comes from a phase 1 study of its ICAM-1 targeting CAR-T autologous candidate AIC100 in patients with relapsed/refractory poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC), which will be reported at the ASCO congress next week.

article thumbnail

AI in action: Enhancing suicide risk detection in behavioral health

Fierce Healthcare

A range of digital health companies today are harnessing natural language processing in different ways to catch those at risk and direct them to resources.

127
127
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Even after sharp sales drop, Pfizer sees bright side with priority review voucher from Paxlovid approval

Fierce Pharma

In a change of pace from the recent COVID-related business struggles for Pfizer, the drugmaker has picked up a valuable reward from the FDA in the form of a priority review voucher (PRV). | The FDA awarded the voucher based on Paxlovid's status as a countermeasure to a material medical threat, according to a notice in the Federal Register.

FDA 117
article thumbnail

Thinking Outside The Pill Bottle: Forging Your Own Path

Pharmacy Times

By venturing beyond the traditional, you can not only shape your own fulfilling career, but also contribute to the future of pharmacy practice and improve patient care for generations to come.

article thumbnail

ADC developer Pheon raises $120m, and other bio financings

pharmaphorum

This week’s round-up of biotech financings is led by a $120 million round for UK-based antibody-drug conjugate (ADC) developer Pheon, with SixPeaks also pulling in nine figures and smaller rounds for Progentos, LabGenius, and Grey Wolf, and Imvax.

105
105
article thumbnail

Can you take benzonatate with NyQuil?

The Checkup by Singlecare

You’ve heard that mixing medications can be dangerous. But when you have a nagging cough that’s keeping you up all night, it can be tempting to try a second treatment if the first doesn’t work. NyQuil , which contains acetaminophen , dextromethorphan, and doxylamine , is a popular over-the-counter (OTC) cough medicine and cold remedy that you probably already have in your medicine cabinet.

Dosage 104
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Nursing homes sue over Biden administration’s minimum staffing rule

STAT

A new federal lawsuit challenging the Biden administration’s new minimum nursing home staffing rule lays out the worst-case scenario: Hundreds of long-term care facilities forced to downsize or close, tens of thousands of vulnerable seniors displaced, and countless others waiting longer for care. Not only that, the complaint argues that the Centers for Medicare and Medicaid Services lacked the authority to implement the final rule.

article thumbnail

How does hydroxychloroquine work for Lupus?

The Checkup by Singlecare

Hydroxychloroquine is a generic prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat malaria, rheumatoid arthritis, and erythematosus lupus. It’s also sold under the brand name Plaquenil. Hydroxychloroquine is considered a first-line treatment for autoimmune inflammatory conditions such as lupus. It’s been shown to reduce lupus flare-ups and help prevent long-term damage from flares.

Dosage 98
article thumbnail

Pharmacy Closures Spark Need for PBM Reform

Pharmacy Times

Multiple states have enacted legislation to rein in PBM practices

144
144
article thumbnail

STAT+: After MDMA therapy, she considered suicide. The trial data tell a different story

STAT

The MDMA study was her last hope. She had read headlines celebrating a 83% response rate in one small, early study of the psychedelic for treating PTSD, and was counting on the new clinical trial to alleviate her own post-traumatic stress disorder. Instead, after her first MDMA session, she felt intense despair when her symptoms didn’t dissipate.

FDA 96
article thumbnail

How is azithromycin used in cats

The Checkup by Singlecare

Azithromycin ( brand name Zithromax ) is a commonly used antibiotic that treats a broad spectrum of bacterial infections in cats, including skin infections, upper respiratory tract infections , pneumonia, bronchitis, and blood infections. Its use in cats is “off-label,” meaning that the U.S. Food and Drug Administration ( FDA ) has not approved the drug for use in companion animals.

Dosage 95
article thumbnail

Pharmacists in Medical Cannabis Care Models: A Review

Pharmacy Times

As medical cannabis use grows, pharmacist involvement is essential.

139
139
article thumbnail

How long does it take for meloxicam to start working?

The Checkup by Singlecare

Meloxicam is a prescription drug originally branded under the name Mobic. As a nonsteroidal anti-inflammatory drug (NSAID), it is prescribed for moderate to severe pain experienced from disorders such as osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis. It may also be used in ankylosing spondylitis. Meloxicam is unique from other over-the-counter NSAID options in that it follows a different metabolic pathway that is less harmful to the gastrointestinal system.

Dosage 94
article thumbnail

Opinion: STAT+: Unmasking the ‘centricity’ illusion in clinical trials

STAT

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

89
article thumbnail

Diazepam for dogs

The Checkup by Singlecare

Diazepam is a generic drug widely known by its brand-name version, Valium. Veterinarians use it in dogs to treat seizures, anxiety, and difficulty peeing due to tightening or obstruction of the urethra. They may also use it as a sedative before veterinary procedures that require anesthesia. Diazepam is a fast-acting sedative that belongs to the benzodiazepine family.

Dosage 90
article thumbnail

FDA advisory committee reviews Novo Nordisk insulin icodec for T1D

Pharmaceutical Technology

The US FDA's EMDAC is set to hold a meeting to assess the benefit-risk profile of Novo Nordisk's insulin icodec, to treat type 1 diabetes.

FDA 98
article thumbnail

ASCO: Merus bispecific garners attention after abstract drop

pharmaphorum

Shares in Merus spike on ASCO abstract on phase 2 trial of EGFRxLGR5 bispecific petosemtamab in head and neck cancer.

110
110
article thumbnail

Opinion: Pandemic lessons must spur federal action to protect nursing home residents

STAT

About one-third of Americans who reach age 65 will need nursing home care in their lifetimes — which can be a daunting thought if you recall the suffering of residents as the Covid-19 pandemic exposed long-standing problems in nursing homes. These problems did not fade away with the end of the public health emergency, and nursing home residents continue to be disproportionately affected by Covid-19.

article thumbnail

NICE, NHS England unveil new pathway for medtech

pharmaphorum

NICE and NHS England are seeking feedback on proposed new rules and commissioning principles for medtech products.

111
111
article thumbnail

Can Pharmacy Automation Help Solve the Industry’s Labor Shortage?

Pharmacy Times

As staffing pressures continue straining pharmacy operations, the right automation solutions offer a path to driving growth and maintaining safety standards, all while better utilizing current personnel.

73
article thumbnail

FDA Roundup: Eyela Biosimilars, Belimumab Autoinjector

Drug Topics

Check out important updates from the FDA for the week of May 20.

FDA 98
article thumbnail

Fierce Pharma Asia—AstraZeneca eyes China's innovation, plots Singapore ADC plant; FDA rejects Hengrui's PD-1 drug

Fierce Pharma

AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore. | AstraZeneca's CEO wants to tap into China's innovation explosion. The company inked an oncology antibody deal with Harbour BioMed, and it plans to build a $1.5 billion ADC plant in Singapore.

FDA 74
article thumbnail

Elevance Health Foundation launches $10M effort to back small businesses to address equity

Fierce Healthcare

Elevance Health's philanthropic arm is launching a new initiative that aims to provide loans to small businesses and other organizations in a bid to address health equity. | Elevance Health's philanthropic arm is launching a new initiative that aims to provide loans to small businesses and other organizations in a bid to address health equity.

73
article thumbnail

More tumult at BIO amid the company’s fourth CEO in four years

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Today, we see some holes in the data for MDMA-assisted therapy, and ponder how that might impact the FDA’s upcoming decision over its approval. Also, the agency’s advisers debate Guardant’s colon cancer liquid biopsy test, and we see new data showing Ozempic’s efficacy in preventing death in diabetes and chronic kidney diseas

FDA 71
article thumbnail

Closing the Gap: Addressing Underrepresentation of Women in Cardiovascular Clinical Trials

Pharmacy Times

Continued disparities of gender representation in cardiovascular research reveal oversights that impact adequate diagnosis and treatment of cardiovascular disease in women.

65
article thumbnail

Weight-loss jabs shouldn’t be quick-fix solution for governments, says expert

The Guardian - Pharmaceutical Industry

Obesity prevention is cheaper long-term option, says Cambridge professor, with focus on dietary advice and exercise plans Skinny jabs risk being used as a cop-out by governments to avoid making hard policy choices to prevent obesity, a leading expert has warned. Prof Giles Yeo, a geneticist at the University of Cambridge and expert on obesity and the brain control of food intake, said drugs such as semaglutide – the active ingredient in the weight-loss jab Wegovy – were remarkable and worked for

75